COVID-19 Convalescent Plasma

Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
COVID-19 Convalescent Plasma is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • The FDA issued an updated Emergency Use Authorization (EUA, 2/4/21) permitting the use of high-titer COVID-19 convalescent plasma to treat hospitalized patients with COVID-19 early in the course of the disease and those hospitalized with impaired humoral immunity.
    • Use of convalescent plasma late in the course of illness (e.g. mechanical ventilation) has not been associated with clinical benefit.
    • The EUA encourages enrollment in available clinical trials prior to pursuing use through the EUA.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • The FDA issued an updated Emergency Use Authorization (EUA, 2/4/21) permitting the use of high-titer COVID-19 convalescent plasma to treat hospitalized patients with COVID-19 early in the course of the disease and those hospitalized with impaired humoral immunity.
    • Use of convalescent plasma late in the course of illness (e.g. mechanical ventilation) has not been associated with clinical benefit.
    • The EUA encourages enrollment in available clinical trials prior to pursuing use through the EUA.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: March 22, 2021